A prospective, single-arm, phase 2 trial exploring the use of pamiparib combined with surufatinib as neoadjuvant therapy for advanced, unresectable ovarian cancer (PASSION).

Authors: Bairong Xia, Wenju Peng, Yao Chen, Wulin Shan, Wenjing Jiang, Wei Xiong

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.5589

Source: Full article


Abstract

5589